Research location
Uppsala
Uppsala County, Sweden
Advertisement
Research activity in Uppsala
Uppsala County, SwedenCureCurrent currently publishes aggregate city-level research activity for this location: 34 trials and 36 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Uppsala
34 linked trials · page 1 of 1A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's PatientsNCT07839793 · 2026-05-25 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation
RECRUITING
APP-based Medical Device for Education and Training of Inhalation TechniqueNCT07145632 · 2025-06-01 · 1 site observation
RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 1 site observation
RECRUITING
The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate CancerNCT06446401 · 2024-10-20 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation
RECRUITING
Cancer Related Major Depression Treated With a Single Dose of PsilocybinNCT06319378 · 2024-04-19 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation
RECRUITING
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT06217822 · 2024-03-07 · 1 site observation
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
Uppsala-Dalarna Dementia and Gait ProjectNCT05893524 · 2015-04-09 · 1 site observation
RECRUITING
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)NCT06305767 · 2024-03-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's DiseaseNCT06107426 · 2024-01-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05595642 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)NCT05508867 · 2022-10-18 · 1 site observation
COMPLETED
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)NCT04811092 · 2022-03-18 · 1 site observation
TERMINATED
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)NCT04732221 · 2021-05-19 · 1 site observation
COMPLETED
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)NCT04576988 · 2021-01-25 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · 2021-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)NCT03924856 · 2019-06-13 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)NCT03820986 · 2019-03-12 · 1 site observation
COMPLETED
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03334487 · 2018-03-15 · 1 site observation
WITHDRAWN
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate CancerNCT03085095 · 2017-04-18 · 1 site observation
COMPLETED
Observational Study of Obstructive Lung Disease (NOVELTY)NCT02760329 · 2016-07-25 · 2 site observations
COMPLETED
Effects of Lignan-rich Diet on Cardiometabolic Risk FactorsNCT02987595 · 2015-06-01 · 1 site observation
COMPLETED
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) SubjectsNCT02198651 · 2015-01-05 · 1 site observation
COMPLETED
A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate CancerNCT02341404 · 2012-05-01 · 1 site observation
COMPLETED
MR-Evaluation of Renal Function-After-Pancreas-transplantationNCT01537445 · 2012-02-01 · 1 site observation
UNKNOWN
Pharmacokinetics in AdolescentsNCT01196689 · 2010-10-01 · 1 site observation
COMPLETED
The Role of the FTO Gene in Reward System Activation in Obese and Healthy SubjectsNCT01863212 · 2010-09-01 · 2 site observations
UNKNOWN
Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of DepressionNCT00627887 · 2008-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.